Contact

Matthew J. Martin, MA

Our Team

Matthew J. Martin, MA

Program Coordinator

Matthew Martin is a Program Coordinator with PORTAL, where he manages the group’s consulting work and supports other PORTAL policy engagements at the federal and state level. He also manages the team’s internal operations and research dissemination strategy. His research focuses on the relationship between prescription drug affordability and market incentives for innovation.

Martin’s previous experience includes work at the National Cancer Institute, Research!America (a health research advocacy alliance) and research institutions in Germany. He holds a Master’s degree in Applied Ethics and Policy from Duke University and a BS in Chemistry from Furman University

Featured Work

Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Characteristics of Academic Inventors on Government-Linked US Drug Patents

Martin MJ, Gabriele SME, Kesselheim AS, Tu SS - JAMA

Research Publications

| December 2024

Innovation Incentives and Competition

Among academic inventors listed on small molecule drug patents tied to US federal funding, most were senior researchers at major research institutions, many of whom had robust grant portfolios and prior industry experience. By contrast, early- and mid-career researchers were less represented, presenting an opportunity for NIH to expand its role in technology transfer by offering patent-related training and financing to these investigators.

View Source

An icon of a bill representing government policy.

Determining Upper Payment Limits: Considerations for State PDABs

Martin MJ, Rome BN, Mooney H, Rand LZG, Raymakers AJN, Bendicksen L, Hwang CS, Lalani HS - National Academy for State Health Policy (NASHP)

Policy Interactions

| February 2024

Price, Value, and Access

This white paper presents three potential strategies state PDABs may use to set upper payment limits (UPLs) for drugs deemed unaffordable: reference pricing, net price benchmarking, and budgetary threshold analyses. It explores the strengths and limitations of each approach and emphasizes that strategies are not mutually exclusive and should be tailored to the underlying drivers of a drug’s unaffordability.

View Source

Conducting Drug Affordability Reviews: Considerations for State PDABs

Martin MJ, Rome BN, Hwang CS, Lalani HS, Raymakers AJN, Rand LZG, Bendicksen L, Mooney H, Liu ITT, Avorn J, Kesselheim AS - National Academy for State Health Policy (NASHP)

Policy Interactions

| September 2023

Price, Value, and Access

This white paper offers comprehensive guidance for state PDABs on conducting drug affordability reviews, covering how to define affordability across multiple perspectives and how to evaluate drug evidence, pricing and spending, comparative effectiveness, economic analyses, patient access, and market dynamics. It emphasizes the need for holistic, indication-specific assessments that account for statutory constraints, stakeholder engagement, and the complexities of the pharmaceutical supply chain.

View Source